IPHA
Innate Pharma S.A.
Price Chart
Latest Quote
$1.48
+0.02 (+1.37%)
Current Price
| Previous Close | $1.46 |
| Open | $1.47 |
| Day High | $1.50 |
| Day Low | $1.47 |
| Volume | 16,811 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 111.70M |
| Total Debt | $22.49M |
| Cash Equivalents | $12.13M |
| Revenue | $10.92M |
| Net Income | $-52.82M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $165.32M |
| EPS (TTM) | $-0.59 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $147.99M |
| Sales | $10.92M |
| Income | $-52.82M |
| Book/sh | $-0.49 |
| Cash/sh | $0.10 |
| Employees | 120 |
Financial Ratios
| Quick Ratio | 0.47 |
| Current Ratio | 0.60 |
Returns & Margins
| ROA | -46.60% |
| Operating Margin | -335.70% |
Ownership
| Insider Ownership | 1.40% |
| Institutional Ownership | 0.35% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.14 |
| P/S | 16.86 |
| P/B | -3.05 |
Analyst Data
| Recommendation | none |
| Target Price | $6.67 |
Technical Indicators
| SMA20 | $1.52 |
| SMA50 | $1.80 |
| SMA200 | $1.72 |
| RSI | 47.35 |
| ATR | 0.1000 |
| Shares Float | 68.87M |
| Short Float | 0.11% |
| Short Ratio | 2.09 |
| Volatility | 1.19 |
| Rel Volume | 0.48 |
Performance History
| Week | -6.21% |
| Month | -12.94% |
| Quarter | -18.68% |
| 6 Months | +5.71% |
| YTD | -18.68% |
| Year | -32.73% |
| 3 Years | -37.02% |
| 5 Years | -74.53% |
| 10 Years | -75.54% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $1.48 | 16,800 |
| 2026-10-26 | $1.46 | 21,900 |
| 2026-10-23 | $1.50 | 11,600 |
| 2026-10-22 | $1.50 | 32,700 |
| 2026-10-21 | $1.57 | 18,800 |
| 2026-10-20 | $1.58 | 13,100 |
| 2026-10-19 | $1.46 | 8,300 |
| 2026-10-16 | $1.43 | 8,000 |
| 2026-10-15 | $1.48 | 7,200 |
| 2026-10-14 | $1.43 | 9,300 |
| 2026-10-13 | $1.47 | 5,600 |
| 2026-10-12 | $1.48 | 33,800 |
| 2026-10-09 | $1.62 | 46,900 |
| 2026-10-08 | $1.48 | 18,400 |
| 2026-10-07 | $1.52 | 13,800 |
| 2026-10-06 | $1.59 | 133,700 |
| 2026-10-05 | $1.58 | 106,900 |
| 2026-10-02 | $1.56 | 92,700 |
| 2026-10-01 | $1.59 | 63,900 |
| 2026-09-30 | $1.63 | 37,800 |
| 2026-09-29 | $1.60 | 31,800 |
| 2026-09-28 | $1.70 | 42,100 |
About Innate Pharma S.A.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
đ° Latest News
No news articles available at the moment. Check back later for updates on IPHA.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $3,115,011 | $14,106,405 | $58,009,390 | $55,415,224 |
| Operating Revenue | $2,555,046 | $14,043,814 | $57,997,095 | $56,104,841 |
| Expenses | ||||
| Interest Expense | $491,785 | $632,614 | $715,324 | $321,896 |
| Total Expenses | $62,827,765 | $71,752,544 | $72,169,443 | $73,773,333 |
| Other Income Expense | $3,765,508 | $259,305 | $2,863,530 | $-46,725,160 |
| Net Non Operating Interest Income Expense | $981,335 | $2,091,204 | $2,835,587 | $288,365 |
| Interest Expense Non Operating | $491,785 | $632,614 | $715,324 | $321,896 |
| Operating Expense | $62,827,765 | $71,752,544 | $72,169,443 | $73,773,333 |
| Other Operating Expenses | $1,780,485 | $317,425 | $-3,576,618 | $-146,418 |
| General And Administrative Expense | $12,293,506 | $13,337,432 | $13,130,659 | $16,176,372 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-54,964,794 | $-55,293,395 | $-8,460,937 | $-64,794,904 |
| Net Interest Income | $981,335 | $2,091,204 | $2,835,587 | $288,365 |
| Interest Income | $1,473,120 | $2,723,818 | $3,550,911 | $610,260 |
| Normalized Income | $-58,730,302 | $-55,552,700 | $-11,324,466 | $-18,069,744 |
| Net Income From Continuing And Discontinued Operation | $-54,964,794 | $-55,293,395 | $-8,460,937 | $-64,941,322 |
| Total Operating Income As Reported | $-60,364,369 | $-57,645,022 | $-14,160,054 | $-64,183,526 |
| Net Income Common Stockholders | $-54,964,794 | $-55,293,395 | $-8,460,937 | $-64,941,322 |
| Net Income | $-54,964,794 | $-55,293,395 | $-8,460,937 | $-64,941,322 |
| Net Income Including Noncontrolling Interests | $-54,964,794 | $-55,293,395 | $-8,460,937 | $-64,941,322 |
| Net Income Discontinuous Operations | $0 | $0 | $0 | $-146,418 |
| Net Income Continuous Operations | $-54,964,794 | $-55,293,395 | $-8,460,937 | $-64,794,904 |
| Pretax Income | $-54,964,794 | $-55,293,395 | $-8,460,937 | $-64,794,904 |
| Special Income Charges | $-651,615 | $0 | $0 | $-45,825,417 |
| Interest Income Non Operating | $1,473,120 | $2,723,818 | $3,550,911 | $610,260 |
| Operating Income | $-59,712,754 | $-57,646,139 | $-14,160,054 | $-18,358,109 |
| Per Share | ||||
| Diluted EPS | $-0.61 | $-0.68 | $-0.10 | $-0.82 |
| Basic EPS | $-0.61 | $-0.68 | $-0.10 | $-0.82 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-52,548,341 | $-52,691,406 | $-9,062,256 | $33,001,006 |
| Total Unusual Items | $3,765,508 | $259,305 | $2,863,530 | $-46,725,160 |
| Total Unusual Items Excluding Goodwill | $3,765,508 | $259,305 | $2,863,530 | $-46,725,160 |
| Reconciled Depreciation | $5,690,176 | $2,228,680 | $1,546,887 | $50,748,855 |
| EBITDA (Bullshit earnings) | $-48,782,833 | $-52,432,101 | $-6,198,726 | $-13,724,154 |
| EBIT | $-54,473,009 | $-54,660,781 | $-7,745,613 | $-64,473,009 |
| Diluted Average Shares | $100,135,243 | $90,591,261 | $94,010,408 | $89,013,078 |
| Basic Average Shares | $100,135,243 | $90,591,261 | $94,010,408 | $89,013,078 |
| Diluted NI Availto Com Stockholders | $-54,964,794 | $-55,293,395 | $-8,460,937 | $-64,941,322 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Impairment Of Capital Assets | $0 | $0 | $0 | $45,825,417 |
| Restructuring And Mergern Acquisition | $651,615 | - | - | - |
| Gain On Sale Of Security | $4,417,123 | $259,305 | $2,863,530 | $-899,743 |
| Research And Development | $48,753,773 | $58,097,687 | $62,615,403 | $57,743,379 |
| Selling General And Administration | $12,293,506 | $13,337,432 | $13,130,659 | $16,176,372 |
| Other Gand A | $3,401,140 | $3,774,450 | $3,248,016 | $4,743,490 |
| Salaries And Wages | $8,892,366 | $9,562,982 | $9,882,642 | $11,432,883 |
Fetched: 2026-10-26
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-24,258,411 | $9,873,701 | $57,544,429 | $58,788,422 |
| Total Assets | $70,100,594 | $124,129,878 | $195,805,301 | $222,750,646 |
| Total Non Current Assets | $17,893,149 | $28,296,636 | $30,373,310 | $66,463,620 |
| Other Non Current Assets | $1,058,455 | $642,674 | $97,239 | $169,889 |
| Non Current Accounts Receivable | $280,541 | $10,425,841 | $11,796,133 | $15,758,355 |
| Investmentin Financial Assets | $11,685,481 | $11,491,003 | $10,948,922 | $39,252,264 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $11,685,481 | $11,491,003 | $10,948,922 | $39,252,264 |
| Goodwill And Other Intangible Assets | $0 | $0 | $464,960 | $1,735,777 |
| Current Assets | $52,207,445 | $95,833,242 | $165,433,109 | $156,288,144 |
| Other Current Assets | $1,118 | - | $1,118 | $2,235 |
| Prepaid Assets | $5,352,632 | $3,720,800 | $10,134,123 | $8,185,984 |
| Receivables | $8,505,644 | $1,836,370 | $51,960,435 | $34,670,840 |
| Other Receivables | $130,770 | $99,475 | $116,240 | $68,179 |
| Taxes Receivable | $7,937,856 | $1,010,395 | $34,818,375 | $31,160,166 |
| Accounts Receivable | $437,018 | $726,501 | $17,025,819 | $3,442,495 |
| Cash Cash Equivalents And Short Term Investments | $38,348,050 | $90,276,072 | $103,337,433 | $113,429,084 |
| Cash And Cash Equivalents | $31,398,235 | $74,210,351 | $78,914,721 | $94,137,701 |
| Non Current Deferred Assets | - | - | $10,065,944 | $9,576,394 |
| Non Current Deferred Taxes Assets | - | - | $10,065,944 | $9,576,394 |
| Other Intangible Assets | - | - | $464,960 | $1,735,777 |
| Debt | ||||
| Total Debt | $25,229,686 | $34,642,898 | $44,588,131 | $47,223,651 |
| Long Term Debt And Capital Lease Obligation | $15,391,752 | $24,908,908 | $34,600,425 | $44,874,260 |
| Long Term Debt | $15,283,335 | $24,792,668 | $34,209,233 | $43,510,675 |
| Current Debt And Capital Lease Obligation | $9,837,935 | $9,733,989 | $9,987,706 | $2,349,391 |
| Current Debt | $9,517,157 | $9,431,094 | $9,445,624 | $1,428,412 |
| Other Current Borrowings | $9,517,157 | $9,431,094 | $9,445,624 | $1,428,412 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $94,359,005 | $114,256,177 | $137,795,912 | $162,226,447 |
| Total Non Current Liabilities Net Minority Interest | $53,396,670 | $77,392,423 | $93,495,028 | $116,023,250 |
| Other Non Current Liabilities | $35,484,521 | $45,968,482 | $50,330,838 | $59,224,322 |
| Non Current Deferred Liabilities | $0 | $3,157,483 | $5,161,507 | $8,853,247 |
| Current Liabilities | $40,962,334 | $36,863,754 | $44,300,884 | $46,203,197 |
| Other Current Liabilities | $7,266,123 | $8,318,990 | $8,545,881 | $11,426,177 |
| Current Deferred Liabilities | $3,157,483 | $688,499 | $6,555,270 | $7,332,067 |
| Payables And Accrued Expenses | $16,812,340 | $17,890,913 | $19,020,901 | $23,372,080 |
| Payables | $16,812,340 | $17,890,913 | $19,020,901 | $23,372,080 |
| Other Payable | $1,141,165 | $1,254,052 | $1,605,007 | $1,427,294 |
| Total Tax Payable | $7,316,419 | $7,781,379 | $7,847,323 | $6,681,569 |
| Accounts Payable | $8,354,756 | $8,855,482 | $9,568,571 | $15,263,217 |
| Non Current Deferred Taxes Liabilities | - | - | $10,065,944 | $9,576,394 |
| Equity | ||||
| Common Stock Equity | $-24,258,411 | $9,873,701 | $58,009,390 | $60,524,199 |
| Total Equity Gross Minority Interest | $-24,258,411 | $9,873,701 | $58,009,390 | $60,524,199 |
| Stockholders Equity | $-24,258,411 | $9,873,701 | $58,009,390 | $60,524,199 |
| Gains Losses Not Affecting Retained Earnings | $1,249,581 | $30,178 | $553,258 | $915,391 |
| Other Equity Adjustments | $1,249,581 | $30,178 | $553,258 | $915,391 |
| Retained Earnings | $-486,802,288 | $-431,836,377 | $-376,542,982 | $-369,191,914 |
| Other Equity Interest | - | - | - | - |
| Other | ||||
| Treasury Shares Number | $20,761 | $20,761 | $20,761 | - |
| Ordinary Shares Number | $104,728,680 | $93,675,827 | $90,356,532 | $88,904,245 |
| Share Issued | $104,749,441 | $93,696,588 | $90,377,293 | $88,904,245 |
| Tangible Book Value | $-24,258,411 | $9,873,701 | $57,544,429 | $58,788,422 |
| Invested Capital | $542,081 | $44,097,464 | $101,664,247 | $105,463,286 |
| Working Capital | $11,245,110 | $58,969,488 | $121,132,225 | $110,084,946 |
| Capital Lease Obligations | $429,194 | $419,135 | $933,274 | $2,284,565 |
| Total Capitalization | $-8,975,076 | $34,666,369 | $92,218,622 | $104,034,874 |
| Additional Paid In Capital | $456,055,669 | $436,994,531 | $429,479,162 | $424,317,655 |
| Capital Stock | $5,238,628 | $4,685,369 | $4,519,951 | $4,483,067 |
| Common Stock | $5,238,628 | $4,685,369 | $4,519,951 | $4,483,067 |
| Employee Benefits | $2,149,324 | $3,051,302 | $2,728,289 | $2,850,117 |
| Non Current Pension And Other Postretirement Benefit Plans | $2,149,324 | $3,051,302 | $2,728,289 | $2,850,117 |
| Non Current Deferred Revenue | $0 | $3,157,483 | $5,161,507 | $8,853,247 |
| Long Term Capital Lease Obligation | $108,416 | $116,240 | $391,193 | $1,363,586 |
| Long Term Provisions | $371,074 | $306,248 | $673,969 | $221,303 |
| Current Deferred Revenue | $3,157,483 | $688,499 | $6,555,270 | $7,332,067 |
| Current Capital Lease Obligation | $320,778 | $302,895 | $542,081 | $920,979 |
| Current Provisions | $3,888,454 | $231,362 | $191,126 | $1,723,483 |
| Investments And Advances | $11,685,481 | $11,491,003 | $10,948,922 | $39,252,264 |
| Net PPE | $4,868,671 | $5,737,119 | $7,066,056 | $9,547,334 |
| Gross PPE | $4,868,671 | $5,737,119 | $7,066,056 | $9,547,334 |
| Construction In Progress | $0 | $0 | $0 | $0 |
| Other Properties | $2,665,698 | $3,183,190 | $3,759,920 | $4,806,080 |
| Land And Improvements | $2,202,973 | $2,553,929 | $3,306,136 | $4,741,254 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $6,949,816 | $16,065,721 | $24,422,712 | $19,291,383 |
| Leases | - | $1,418,353 | $1,872,136 | - |
Fetched: 2026-10-26
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-39,018,666 | $-8,144,630 | $-59,120,377 | $-22,663,463 |
| Operating Activities | ||||
| Operating Cash Flow | $-36,390,970 | $-7,707,612 | $-58,963,899 | $-21,409,411 |
| Cash Flow From Continuing Operating Activities | $-36,390,970 | $-7,707,612 | $-58,963,899 | $-21,409,411 |
| Operating Gains Losses | $344,249 | $-604,672 | $646,027 | $-611,378 |
| Investing Activities | ||||
| Capital Expenditure | $-2,627,696 | $-437,018 | $-156,477 | $-1,254,052 |
| Investing Cash Flow | $23,058,009 | $10,282,777 | $8,146,865 | $2,097,910 |
| Cash Flow From Continuing Investing Activities | $23,058,009 | $10,281,659 | $8,145,747 | $2,097,910 |
| Net Other Investing Changes | $70,415 | $1,118 | $6,706 | $-1,118 |
| Financing Activities | ||||
| Financing Cash Flow | $-2,197,385 | $-6,715,100 | $6,784,397 | $-2,043,143 |
| Cash Flow From Continuing Financing Activities | $-2,197,385 | $-6,715,100 | $6,784,397 | $-2,043,143 |
| Cash Dividends Paid | - | - | $0 | $0 |
| Issuance Of Capital Stock | - | - | - | - |
| Net Other Financing Charges | - | - | - | - |
| Net Common Stock Issuance | - | - | - | - |
| Common Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-2,638,873 | $-9,987,706 | $-9,959,763 | $-2,264,446 |
| End Cash Position | $78,914,721 | $74,210,351 | $31,398,235 | $94,137,701 |
| Beginning Cash Position | $94,137,701 | $78,914,721 | $74,210,351 | $115,967,365 |
| Effect Of Exchange Rate Changes | $306,248 | $-564,435 | $1,220,521 | $-478,373 |
| Changes In Cash | $-15,529,228 | $-4,139,935 | $-44,032,637 | $-21,351,291 |
| Proceeds From Stock Option Exercised | $441,489 | $3,272,605 | $16,744,160 | $221,303 |
| Net Issuance Payments Of Debt | $-2,638,873 | $-9,987,706 | $-9,959,763 | $-2,264,446 |
| Net Long Term Debt Issuance | $-2,638,873 | $-9,987,706 | $-9,959,763 | $-2,264,446 |
| Long Term Debt Payments | $-2,638,873 | $-9,987,706 | $-9,959,763 | $-2,264,446 |
| Interest Received Cfi | $0 | $0 | $433,665 | $0 |
| Net Investment Purchase And Sale | $25,447,637 | $10,718,677 | $7,862,971 | $3,353,079 |
| Sale Of Investment | $25,447,637 | $10,718,677 | $7,862,971 | $3,353,079 |
| Net Intangibles Purchase And Sale | $-2,235,386 | $0 | $0 | $-656,086 |
| Purchase Of Intangibles | $-2,235,386 | $0 | $0 | $-656,086 |
| Net PPE Purchase And Sale | $-224,656 | $-437,018 | $-156,477 | $-597,966 |
| Sale Of PPE | $167,654 | $0 | $0 | $0 |
| Purchase Of PPE | $-392,310 | $-437,018 | $-156,477 | $-597,966 |
| Change In Working Capital | $-35,869,007 | $43,771,097 | $-11,883,313 | $-13,974,517 |
| Other Non Cash Items | $6,706 | $-397,899 | $-395,663 | $148,653 |
| Stock Based Compensation | $4,756,902 | $4,408,182 | $2,869,118 | $4,749,078 |
| Unrealized Gain Loss On Investment Securities | $-1,779,367 | $-1,492,120 | $-504,080 | $1,533,475 |
| Provisionand Write Offof Assets | $-1,079,692 | $-327,484 | $3,721,918 | $937,745 |
| Depreciation Amortization Depletion | $5,690,176 | $2,228,680 | $1,546,887 | $50,748,855 |
| Depreciation And Amortization | $5,690,176 | $2,228,680 | $1,546,887 | $50,748,855 |
| Pension And Employee Benefit Expense | $318,543 | $362,133 | $-901,978 | $407,958 |
| Net Foreign Currency Exchange Gain Loss | $608,025 | $-989,158 | $1,522,298 | $-1,019,336 |
| Gain Loss On Sale Of PPE | $525,316 | $22,354 | $25,707 | $0 |
| Net Income From Continuing Operations | $-8,460,937 | $-55,293,395 | $-54,964,794 | $-64,941,322 |
| Issuance Of Debt | - | - | $0 | $0 |
| Interest Paid Cff | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Purchase Of Investment | - | - | $0 | $0 |
| Change In Other Working Capital | - | - | - | $-26,189,785 |
| Change In Other Current Liabilities | - | - | - | $25,478,932 |
| Change In Payables And Accrued Expense | - | - | - | $-8,563,765 |
| Change In Payable | - | - | - | $-8,563,765 |
| Change In Account Payable | - | - | - | $-8,563,765 |
| Change In Receivables | - | - | - | $-4,698,782 |
| Changes In Account Receivables | - | - | - | $-4,698,782 |
| Gain Loss On Investment Securities | - | - | - | $-1,019,336 |
Fetched: 2026-10-26